Yarra Pharmaceuticals Private Limited - Company Profile

It is a chemicals private limited company based in Aurangabad, Maharashtra, India, established in 2018.
2018 Aurangabad, Maharashtra, India Active
Last Updated:
Access Report
About Yarra Pharmaceuticals Private Limited

Yarra Pharmaceuticals Private Limited, a active private limited company, was established on 06 April 2018 in Aurangabad, Maharashtra, India. Engaging in manufacturing within the chemicals sector, it holds CIN: U24299MH2018PTC307614. Registered under ROC Roc Mumbai Ii. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.

Its leadership includes Rajesh Petras Salve (Additional Director), Sachin Dattatray Jogdankar (Director). Past directors included Pratik Vilasrao Kamble. It is based at Flat. No: 13, Sai Shilp Apt Pratap Nagar, Aurangabad, Maharashtra, 431001.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24299MH2018PTC307614

  • Registration Number

    307614

  • Incorporation Date

    06 April 2018

  • Authorized Capital

    ₹0.10 M

  • Paid-Up Capital

    ₹0.10 M

  • ROC Code

    Roc Mumbai Ii

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 0.10 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 7 Year, 11 Months
Company report

Yarra Pharmaceuticals Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Yarra Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Yarra Pharmaceuticals Private Limited?
Current Directors
Name Designation Appointment Date Status
Rajesh Petras Salve Additional Director 16 Feb 2019 Current
Sachin Dattatray Jogdankar Director 06 Apr 2018 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 16 Feb 2019 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Yarra Pharmaceuticals.

Enhance accessibility to Yarra Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Yarra Pharmaceuticals revenue growth over time
Yarra Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Yarra Pharmaceuticals?

Unlock access to Yarra Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Yarra Pharmaceuticals?

Unlock and access historical data on people associated with Yarra Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Yarra Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Yarra Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Yarra Pharmaceuticals
Recent Activity within the Organization
  • Director Appointment

    The activity Rajesh Petras Salve was appointed as a Additional Director was appointed as a Additional Director on 16 Feb 2019 & has been associated with this company since 7 years 1 month . was completed.

  • Director Appointment

    Progress on Sachin Dattatray Jogdankar was appointed as a Director was appointed as a Director on 06 Apr 2018 & has been associated with this company since 7 years 11 months . was documented.

  • Company Incorporation

    Progress on Yarra Pharmaceuticals Private Limited was registered on 06 Apr 2018 with Roc Mumbai Ii & aged 7 years 11 months as per MCA records. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Yarra Pharmaceuticals Private Limited?

The CIN of Yarra Pharmaceuticals Private Limited is U24299MH2018PTC307614.

Where is Yarra Pharmaceuticals Private Limited headquartered?

Yarra Pharmaceuticals Private Limited is headquartered at Flat. No: 13, Sai Shilp Apt Pratap Nagar, Aurangabad, Maharashtra, 431001.

When was Yarra Pharmaceuticals Private Limited incorporated?

Yarra Pharmaceuticals Private Limited was incorporated on 06 April 2018.

Who are the current directors of Yarra Pharmaceuticals Private Limited?

The current directors of Yarra Pharmaceuticals Private Limited are

What is the primary industry of Yarra Pharmaceuticals Private Limited?

The primary industry of Yarra Pharmaceuticals Private Limited is Chemicals.

Is Yarra Pharmaceuticals Private Limited a listed company?

Yarra Pharmaceuticals Private Limited is unlisted.

What is the capital structure of Yarra Pharmaceuticals Private Limited?

The authorized capital of Yarra Pharmaceuticals Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available